Form 4 for CCCC C4 Therapeutics, Inc.
Accepted 2023-09-19 00:00:00 ET · period of report 2023-09-18 · accession 0001662579-23-000097 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-09-19 | 2023-09-18 | CCCC | Adams Kendra | CFO | A - Grant | $0.00 | +25.0K | 46.6K | +116% | $0 |
| D | 2023-09-19 | 2023-09-18 | CCCC | Adams Kendra | CFO | A - Grant | $0.00 | +111.0K | 111.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-18 | A | A | 25,000 | $0.00 | 46,640 | D | — | — | (F1) Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on September 18, 2024, subject to the Reporting Person's continued service on each vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-09-18 | A | A | 111,000 | $0.00 | 111,000 | D | $2.15 · — to 2033-09-17 | 111,000 Common Stock | (F2) 25% of this option shall vest and become exercisable on September 18, 2024, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service on each vesting date. |